Skip to main content
. Author manuscript; available in PMC: 2013 Jun 17.
Published in final edited form as: Semin Hematol. 2010 Jan;47(1):22–36. doi: 10.1053/j.seminhematol.2009.10.009

Figure 5A and 5B.

Figure 5A and 5B

(A) Cumulative incidence of relapse after nonmyeloablative umbilical cord blood transplantation for patients with follicular lymphoma/chronic lymphocytic leukemia (—), large-cell /mantle-cell lymphoma (---), and HL (- - -).

Reprinted from Biol Blood Marrow Transplant, Vol 15, Brunstein CG, Cantero S, Cao Q, et al., Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation, 214-222, ©2009, with permission from Elsevier.

(B) Estimated progression-free survival (PFS) according to histologic subtype. Patients with indolent non-Hodgkin’s lymphoma (NHL); yellow line), mantle-cell lymphoma (blue line), aggressive NHL (grey line) and Hodgkin’s lymphoma (red line).

Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved. Rodrigues, CA et al: J Clin Oncol 27(2), 2009:256-263.